Patients
ASCO 2026: Quality of life, not just quantity, with Dr Harol...
Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.
Oncology
ASCO 2026: Are radiopharmaceuticals being systematically und...
The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.
Market Access
Industry exercises option for midpoint review of VPAG Invest...
Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?
Oncology
ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...
Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.
Digital
The pulse of progress: AI, real-world data, and the ethics o...
What kind of data should train and power the next generation of healthcare AI?
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
